Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. The firm is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.
Follow-Up Questions
Qui est le CEO de Cynata Therapeutics Ltd ?
Dr. Kilian Kelly est le Chief Executive Officer de Cynata Therapeutics Ltd, il a rejoint l'entreprise depuis 2019.
Quelle est la performance du prix de l'action CYYNF ?
Le prix actuel de CYYNF est de $0.118, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Cynata Therapeutics Ltd ?
Cynata Therapeutics Ltd appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Cynata Therapeutics Ltd ?
La capitalisation boursière actuelle de Cynata Therapeutics Ltd est de $28.0M
